OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics has 70 employees and is listed on Euronext Paris. The Company relies upon its international and complementary team of experts involved in the research and optimisation of drug candidates, pharmaceutical development and drug registration to develop the next wave of novel immunotherapies. Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Clinical Services
- Market Focus:
- Internationally (various countries)
About Us
A clinical-stage biotechnology company in immunotherapy
Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.
Management Team
The Company relies upon its international and complementary team of experts involved in the research and optimisation of drug candidates, pharmaceutical development and drug registration to develop the next wave of novel immunotherapies.
Board of Directors
Members of the Board of Directors combine international expertise in both drug development, marketing, industry and finance, with experience in listed biotech companies.
Our Partnerships
OSE Immunotherapeutics values collaborations and partnerships with pharmaceutical leaders, clinical organizations and academic laboratories as a fundamental element of both its long-term strategy and day-to-day operations.
Sharing knowledge and bringing together key expertise to develop breakthrough innovations and to ensure the fastest possible delivery of new therapies to patients in need are fundamental to how OSE’s research teams operate.
Having our product development supported by an international network of pharmaceutical, clinical and academic collaborators allows us increased scale and capacity to enhance the value of our assets.